Sign up for updates on ENJAYMO
Subscribe now for future updates on ENJAYMO and Cold Agglutinin Disease (CAD)
All fields are required.
JOIN US AT THE ASH ANNUAL MEETING FOR A PRESENTATION ON ENJAYMO | MONDAY 12/12 @ 8 am
VISIT US AT ASH | DECEMBER 10-13 | BOOTH #643
Subscribe now for future updates on ENJAYMO and Cold Agglutinin Disease (CAD)
All fields are required.
ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients.
Serious Infections
Infusion-Related Reactions
Risk of Autoimmune Disease
Recurrent Hemolysis After ENJAYMO Discontinuation
ENJAYMO® (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).
Please see full Prescribing Information.
See the full Medication Guide.
Learn more about Sanofi’s commitment to fighting counterfeit drugs.
ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients.
Serious Infections
Infusion-Related Reactions
Risk of Autoimmune Disease
Recurrent Hemolysis After ENJAYMO Discontinuation
ENJAYMO® (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).
Please see full Prescribing Information.
See the full Medication Guide.
Learn more about Sanofi’s commitment to fighting counterfeit drugs.